| 臺大學術典藏 |
2020-08-13T06:33:29Z |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Spataro V.; Unk M.; Chih-Hsin Yang J.; Lorence R.M.; Carri?re P.; Cseh A.; Chang G.-C.; Gautschi O.; Liao W.-Y.; Peters S.;Curioni-Fontecedro A.;Nechushtan H.;Jin-Yuan Shih;Liao W.-Y.;Gautschi O.;Spataro V.;Unk M.;Chih-Hsin Yang J.;Lorence R.M.;Carri?Re P.;Cseh A.;Chang G.-C.; Peters S.; Curioni-Fontecedro A.; Nechushtan H.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-08-13T06:33:29Z |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Spataro V.; Unk M.; Chih-Hsin Yang J.; Lorence R.M.; Carri?re P.; Cseh A.; Chang G.-C.; Gautschi O.; Liao W.-Y.; Peters S.;Curioni-Fontecedro A.;Nechushtan H.;Jin-Yuan Shih;Liao W.-Y.;Gautschi O.;Spataro V.;Unk M.;Chih-Hsin Yang J.;Lorence R.M.;Carri?Re P.;Cseh A.;Chang G.-C.; Peters S.; Curioni-Fontecedro A.; Nechushtan H.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation?�Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Chang G.-C.;Cseh A;Carri?re P;Lorence R.M;Chih-Hsin Chih-Hsin Yang;Unk M;Spataro V;Gautschi O;Liao W.-Y;Shih J.-Y;Nechushtan H;Curioni-Fontecedro A;Peters S; Peters S; Curioni-Fontecedro A; Nechushtan H; Shih J.-Y; Liao W.-Y; Gautschi O; Spataro V; Unk M; Chih-Hsin CHIH-HSIN YANG; Lorence R.M; Carrière P; Cseh A; Chang G.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation?�Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Chang G.-C.;Cseh A;Carri?re P;Lorence R.M;Chih-Hsin Chih-Hsin Yang;Unk M;Spataro V;Gautschi O;Liao W.-Y;Shih J.-Y;Nechushtan H;Curioni-Fontecedro A;Peters S; Peters S; Curioni-Fontecedro A; Nechushtan H; Shih J.-Y; Liao W.-Y; Gautschi O; Spataro V; Unk M; Chih-Hsin CHIH-HSIN YANG; Lorence R.M; Carrière P; Cseh A; Chang G.-C. |
| 臺大學術典藏 |
2018 |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Peters S.;Curioni-Fontecedro A.;Nechushtan H.;Shih J.-Y.;Wei-Yu Liao;Gautschi O.;Spataro V.;Unk M.;Chih-Hsin Yang J.;Lorence R.M.;Carri?Re P.;Cseh A.;Chang G.-C.; Peters S.; Curioni-Fontecedro A.; Nechushtan H.; Shih J.-Y.; WEI-YU LIAO; Gautschi O.; Spataro V.; Unk M.; Chih-Hsin Yang J.; Lorence R.M.; Carri?re P.; Cseh A.; Chang G.-C. |
| 臺大學術典藏 |
2018 |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Peters S.;Curioni-Fontecedro A.;Nechushtan H.;Shih J.-Y.;Wei-Yu Liao;Gautschi O.;Spataro V.;Unk M.;Chih-Hsin Yang J.;Lorence R.M.;Carri?Re P.;Cseh A.;Chang G.-C.; Peters S.; Curioni-Fontecedro A.; Nechushtan H.; Shih J.-Y.; WEI-YU LIAO; Gautschi O.; Spataro V.; Unk M.; Chih-Hsin Yang J.; Lorence R.M.; Carri?re P.; Cseh A.; Chang G.-C. |
